JB Pharma-Torrent merger: 51:100 swap awaits NCLT

What has been approved so far

J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) and Torrent Pharmaceuticals Limited have received shareholder approval for their proposed scheme of amalgamation. The vote clears a major internal milestone and moves the transaction into its final regulatory stretch. Companies described the step as important for building a stronger combined market presence and improving operational capability. The proposed structure remains an amalgamation of JB Pharma into Torrent Pharma, with Torrent as the transferee company. With shareholder consent in place, the focus now shifts to tribunal clearance and completion of filings.

Share swap ratio and who receives shares

Under the approved share exchange arrangement, JB Pharma shareholders, excluding Torrent Pharma, will receive 51 equity shares of Torrent Pharma for every 100 equity shares held in JB Pharma. The share swap ratio was determined by an independent registered valuer, as disclosed by the companies. The ratio has been reiterated across company communications around the scheme. The swap is the key economic term for minority shareholders, as it determines post-merger ownership through Torrent shares.

Public shareholder approval and SEBI-related compliance

JB Pharma said the merger proposal secured approval from the requisite majority of public shareholders in line with SEBI regulations. This public shareholder vote matters because it is often a gating condition for listed-company schemes. The companies have also referred to clearance letters from stock exchanges as part of the approvals already obtained. With these steps done, remaining approvals are primarily tribunal-led and procedural filings.

NCLT Ahmedabad Bench is the next gate

The proposed amalgamation is awaiting final approval from the National Company Law Tribunal (NCLT), Ahmedabad Bench. Company communication notes that after the tribunal’s approval and completion of regulatory filings, JB Pharma will stand amalgamated with Torrent Pharma. In other words, shareholder approval alone does not complete the scheme. The NCLT’s sanction is central to legally effecting the amalgamation under the Companies Act process.

What Torrent told investors about the timeline

Torrent Pharmaceuticals has said the merger is now in its concluding phase. Aman Mehta, managing director of Torrent Pharmaceuticals and a board member of JB Chemicals, told investors that necessary shareholder approval has been obtained and the process is in its final stage. He added that a hearing is scheduled for the second week of June. Torrent said it expects the merger to take effect within the next one to two months, based on the hearing schedule and subsequent steps.

Key legal and process references in filings

The scheme process referenced Sections 230 to 232 of the Companies Act, 2013, which govern arrangements and amalgamations. Shareholder approval was cited as being secured under Section 230(6), which requires a majority of equity shareholders and three-fourths in value of shareholders who cast their votes. The NCLT Ahmedabad Bench had directed the companies to convene shareholder meetings as part of the process. Torrent also disclosed that an NCLT-convened meeting of equity shareholders was held on April 28, 2026, where shareholders approved the scheme.

Appointed date, board approval date, and meeting mechanics

The scheme states an appointed date of 21 January 2026 for the amalgamation. The boards of both companies approved the scheme on 29 June 2025. Separate disclosures also indicated that JB Chemicals published newspaper advertisements for an equity shareholders meeting scheduled for April 28, 2026 to consider the amalgamation. The meeting was to be conducted via video conferencing, with remote e-voting available from April 24 to April 27, 2026. These details reflect the compliance-heavy structure typical of tribunal-led mergers.

Corrigendum order and what it signals

Torrent Pharmaceuticals confirmed receipt of a Corrigendum Order from the NCLT, Ahmedabad Bench, as a procedural clarification linked to the ongoing amalgamation. The corrigendum was dated March 24, 2026 and was uploaded on the NCLT website on March 25, 2026, following earlier intimation about the tribunal’s order. Disclosures describe the corrigendum as a correction or clarification to the tribunal’s sanctioning order. The companies have indicated that such procedural updates do not alter the fundamental terms or the share swap ratio already announced.

Regulatory context and deal sizing disclosed

The merger has been described as having an approximate equity valuation of ₹25,689 crore in market reporting cited in the provided text. The transaction has also secured approval from the Competition Commission of India (CCI) on October 21, 2025, as noted in the disclosures. Some communications describe JB Chemicals as Mumbai-based, while tribunal-related references place both entities under the Registrar of Companies, Gujarat and under the NCLT Ahmedabad Bench’s jurisdiction. Taken together, these details underline that the remaining milestones are administrative and tribunal-led rather than commercial renegotiations.

Summary table of key disclosed terms

Timeline of major milestones mentioned

Why the NCLT step matters for operations

Multiple disclosures note that NCLT clearance is the last major regulatory gate before post-merger integration can proceed. The process can include consolidation of manufacturing sites, product licences, and GMP-certified facilities under a single legal entity, as referenced in the provided text. But those operational changes are contingent on the tribunal’s order and completion of required filings. Until then, the approved scheme remains pending implementation even after shareholder votes.

Conclusion

JB Pharma and Torrent Pharma have crossed the key shareholder-approval milestone for their amalgamation, with the share swap fixed at 51 Torrent shares for every 100 JB Pharma shares held by eligible shareholders. The scheme now awaits NCLT Ahmedabad Bench clearance and completion of regulatory filings. Torrent has indicated a hearing in the second week of June and expects the merger to take effect within one to two months after that, subject to the tribunal process. The next disclosed trigger for investors is the outcome of the NCLT proceedings and subsequent statutory filings.